8legs: Pharmaceutical benefits scheme

#1 out of 1

‘Problematic precedent’: expert says Australia could be next as UK agrees to pay 25% more for new US medicines

The UK will pay 25% more for new US medicines under a recent deal, prompting concern from health experts about funding NHS services.
Australia’s PBS remains central as officials say they won’t compromise access to affordable medicines while engaging with the US on pricing dynamics.
Experts warn the deal could set a precedent affecting global medicine pricing and threaten funding for health services in other countries.
Australian experts say the deal could lead to pressure to approve more high-cost drugs that may not meet value-for-money standards.
Experts say the implications are global and that Australia should monitor the UK-US arrangement as it negotiates its own pricing framework.
Medicines Australia urges reform of the Health Technology Assessment to speed access to new medicines while maintaining value.
NHS funding concerns are tied to spending constraints on staff and proven treatments amid broader budget pressures.
UK officials say the deal aims to shift global pharmaceutical policy, with the US hoping other countries follow.
Australia’s Health Minister emphasizes PBS protections during ongoing discussions with US representatives.

Vote 0